BeiGene

Yahoo Finance • 29 days ago

A Fresh Look at BeOne Medicines (ONC) Valuation as Shares Gain Momentum

BeOne Medicines (ONC) shares saw a modest 2% bump in the latest trading session. Investors have been keeping an eye on the company's progress, especially given its ongoing focus on innovative cancer therapies and recent leadership moves.... Full story

Yahoo Finance • 30 days ago

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied

Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the Inflation Reduction Act. Continue Reading View Comments... Full story

Yahoo Finance • 30 days ago

U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

If approved, sonrotoclax will become the first BCL2 inhibitor for R/R MCL in the U.S., addressing a high unmet need in an aggressive cancer Sonrotoclax previously received Breakthrough Therapy Designation based on clinically meaningful, r... Full story

Yahoo Finance • last month

US Stock Market Today: S&P 500 Futures Slip as Rate Cut Bets Rise Amid Weak Jobs Data

The Morning Bull - US Market Morning Update Tuesday, Nov, 25 2025 US stock futures are slipping this morning, with S&P 500 contracts down around 0.1 percent. The key factor driving the mood is a drop in the 10-year Treasury yield to 4.04... Full story

Yahoo Finance • last month

Zymeworks shifts to a royalty-driven business model

[Golden Percentage Symbol] fatido Zymeworks (ZYME [https://seekingalpha.com/symbol/ZYME]) on Tuesday announced plans to focus on a royalty-driven growth model backed by its internal R&D engine and licensing arrangements with companies suc... Full story

Yahoo Finance • last month

Jazz, Zymeworks’ Ziihera trial shows significant PFS improvement, shares rally

[Biomedical Researchers Conduct Experiments in a Modern Laboratory. Female Scientist Preparing a Set of Samples in Test Tubes with Purple Caps. Colleague Analyzes Data on a Computer in the Background] gorodenkoff/iStock via Getty Images... Full story

Yahoo Finance • last month

Saudi sovereign wealth fund cuts holdings of U.S. stocks

[World Map with Saudi Arabia Flag Overlay] Hacer Keles/iStock via Getty Images Saudi Arabia’s Public Investment Fund trimmed its exposure to U.S. equities in the third quarter, shedding stakes in nearly a dozen American companies and push... Full story

Yahoo Finance • last month

Stock Market Today: Dow Hits New Highs; Lilly, Barrick, Goldman Break Out (Live Coverage)

Stock Market Today: The Dow Jones index rose Wednesday to new highs and AMD rallied sharply. Gold and silver stocks jammed. Continue Reading View Comments... Full story

Yahoo Finance • last month

IBD Stock Of The Day BeOne Breaks Out As It Takes On Cancer Giants J&J, AbbVie

BeOne Medicines is Wednesday's IBD Stock Of The Day. The IBD 50 biotech is breaking out after a record-breaking quarter. Continue Reading View Comments... Full story

Yahoo Finance • last month

BeOne, IBD Stock Of The Day, Breaks Out As It Takes On Cancer Giants J&J, AbbVie

BeOne Medicines is Wednesday's IBD Stock Of The Day. The IBD 50 biotech is breaking out after a record-breaking quarter. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

How Strong BRUKINSA Sales and Patent Resolution at BeOne Medicines (ONC) Have Changed Its Investment Story

BeOne Medicines Ltd. recently reported third quarter 2025 results, achieving US$1.41 billion in revenue and US$124.84 million in net income, a shift from a net loss during the same period last year, attributed to a very large increase in s... Full story

Yahoo Finance • 2 months ago

BeiGene Q3 2025 Earnings Preview

* BeiGene (ONC [https://seekingalpha.com/symbol/ONC]) is scheduled to announce Q3 earnings results on Thursday, November 6th, before market open. * The consensus EPS Estimate is $0.86 [https://seekingalpha.com/symbol/ONC/earnings/estim... Full story

Yahoo Finance • 2 months ago

BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6

SAN CARLOS, Calif., October 22, 2025--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2025 financial results on Thursday, November 6, 2025 before the f... Full story

Yahoo Finance • 2 months ago

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as Trump Softens China Rhetoric

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 1.1% and the actively trad PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

Here’s Why BeOne Medicines Ltd. (ONC) Declined in Q2

Baird Asset Management, which controls Chautauqua Capital Management, a boutique investment firm, released its second quarter 2025 investor letter for the "Baird Chautauqua International and Global Growth Fund". A copy of the letter can be... Full story

Yahoo Finance • 3 months ago

Trump’s 100% drug tariffs send pharma stocks lower

[Many different pills on pink background. Prescription pills and vitamins. Flat lay and space for text.] Baurzhan Ibrashev European and Asian pharmaceutical stocks fell Friday after President Donald Trump unveiled sweeping new tariffs, in... Full story

Yahoo Finance • 4 months ago

ONC Crosses Above Average Analyst Target

In recent trading, shares of BeOne Medicines Ltd (Symbol: ONC) have crossed above the average analyst 12-month target price of $345.89, changing hands for $346.45/share. When a stock reaches the target an analyst has set, the analyst logi... Full story

Yahoo Finance • 4 months ago

BeOne Medicines succeeds in Phase 1/2 study for lymphoma therapy

[Lymphoma blood test] BeOne Medicines (NASDAQ:ONC [https://seekingalpha.com/symbol/ONC]) announced Friday that sonrotoclax, its experimental therapy targeting a hematological cancer called mantle cell lymphoma, succeeded as a late-line op... Full story

Yahoo Finance • 4 months ago

Royalty Pharma to buy royalty interest in Amgen’s Imdelltra for up to $950M

BeOne Medicines (NASDAQ:ONC [https://seekingalpha.com/symbol/ONC]) is selling its royalty rights on the worldwide sales, excluding China, of Amgen’s (NASDAQ:AMGN [https://seekingalpha.com/symbol/AMGN]) cancer drug Imdelltra (tarlatamab-dll... Full story

Yahoo Finance • 4 months ago

This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine

Biotech stocks are performing well in the stock market in August and a few in the IBD 50 have formed bases with clear buy points. Continue Reading View Comments... Full story